Prescription Medicines
Dapazin Tab. 5mg
- Product Category
- diabetes medication
- Active Ingredients
- Dapagliflozin
- Appearance
- Yellow, round, biconvex film-coated tablets
- Reimbursement Code
- 648105110
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Dapagliflozin bis L-proline (in-house specification) ----- 7.815mg (5mg as dapagliflozin)
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry II yellow (85F92582), silicon dioxide, low-substituted hydroxypropyl cellulose
2. Effectiveness
1. Type 2 diabetes: This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
- monotherapy
- Combination therapy
For the effect on cardiovascular events in patients with inadequately controlled type 2 diabetes and established cardiovascular disease or cardiovascular risk factors, see “Precautions for Use, 11. Information for Healthcare Professionals, 3) Clinical Study Information.”
2. Chronic heart failure: Reduces the risk of death due to cardiovascular disease, hospitalization due to heart failure, and emergency hospital visit due to heart failure in patients with chronic heart failure (NYHA class II-IV).
This drug is administered in combination with other standard heart failure treatments.
3. Chronic kidney disease: In patients with chronic kidney disease, the estimated glomerular filtration rate (eGFR) continues to decline, reaching end-stage renal disease, and reducing the risk of death from cardiovascular disease and kidney-related death.
This drug is administered in combination with other standard treatments for kidney disease.
3. Dosage and dosage
type 2 diabetes
Monotherapy and additional combination therapy
The recommended dose of this drug is 10 mg once daily for monotherapy and additional combination therapy with other hypoglycemic agents such as insulin. If this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycemia.
Early combination therapy
When co-administered with metformin in those who have not previously received diabetes medication, the initial recommended dose of this drug is 5 mg once daily or 10 mg once daily.
Chronic heart failure and chronic kidney disease
The recommended dose of this drug is 10 mg once a day.
special group
renal impairment
- eGFR less than 45 mL/min/1.73m2: It is not recommended to administer this drug to improve glycemic control.
- eGFR less than 25 mL/min/1.73m2: It is not recommended to start treatment with this drug in patients with chronic heart failure and chronic kidney disease.
-Patients on dialysis: Do not administer this drug.
liver failure
No dose adjustment is necessary for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10 mg.
Elderly (≥ 65 years): Dosage adjustment based on age is not recommended.
Children: The effectiveness and safety of dapagliflozin in children under 18 years of age have not been established. There is no relevant data.
Method of administration: This drug can be administered orally, once a day, at any time of the day, regardless of food intake. Tablets should be swallowed whole.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with a history of hypersensitivity to the main ingredients or excipients of this drug
2) Patients with type 1 diabetes or diabetic ketoacidosis
3) This medicine contains lactose anhydrous. It should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
4) Patients on dialysis
2. Administer with caution to the following patients:
1) Administration in patients with decreased body volume and renal dysfunction
This drug may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients receiving SGLT-2 inhibitors, including this drug, and some required hospitalization and dialysis. The risk of hypovolemia or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2), the elderly, and those using loop diuretics. For patients with these characteristics, it is necessary to evaluate body fluid status and renal function before starting treatment with this drug, and monitor symptoms and signs of hypotension and renal function after starting treatment.
The glucose-lowering efficacy of this medicine depends on renal function. Efficacy is reduced in patients with moderate renal impairment, and this medicine is not recommended solely for glycemic control in patients with type 2 diabetes and an eGFR below 45 mL/min/1.73 m² (see Dosage and Administration). Among patients with moderate renal impairment, elevated creatinine, phosphorus and parathyroid hormone (PTH) levels and hypotension were reported more frequently with this medicine than with placebo.
There is limited experience in starting this drug in patients with an eGFR of less than 25mL/min/1.73m2.
It is not recommended to start treatment with this drug in patients with chronic heart failure and chronic kidney disease whose eGFR is less than 25mL/min/1.73m2 (see Dosage and Administration section).
3. Adverse reactions
1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with type 2 diabetes (DECLARE; see section ‘11. Information for experts, 3) Clinical trial information’), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the median exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure.
The most commonly reported adverse reactions throughout clinical studies were genital infections.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with chronic heart failure with reduced left ventricular systolic function (LVEF≤40%) (DAPA-HF; see section ‘11. Information for experts, 3) Clinical trial information’), 2,368 people were administered dapagliflozin 10 mg and 2,368 people were administered placebo, and the median exposure period was 18 months. The study population included patients with type 2 diabetes or without diabetes and an eGFR of 30 mL/min/1.73m2 or higher.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with heart failure whose left ventricular ejection fraction (LVEF) exceeded 40% (DELIVER; see section ‘11. Information for experts, 3) Clinical trial information’), 3,126 people were administered dapagliflozin 10 mg and 3,127 people were administered placebo, and the median exposure period was 27 months. The study population included patients with type 2 diabetes or without diabetes and an eGFR of 25 mL/min/1.73m2 or higher.
In a clinical trial to evaluate the renal effects of dapagliflozin in patients with chronic kidney disease (DAPA-CKD; see section ‘11. Information for experts, 3) Clinical trial information’), 2,149 people were administered dapagliflozin 10 mg and 2,149 people were administered placebo, and the median exposure period was 27 months. The study population included patients with type 2 diabetes or without diabetes and an eGFR greater than 25 mL/min/1.73m2 or less than 75 mL/min/1.73m2. Treatment was continued when eGFR decreased below 25 mL/min/1.73m2.
The safety profile of dapagliflozin was consistent across the efficacy and effects studied. Diabetic ketoacidosis was observed only in diabetic patients.
2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and unknown (cannot be assessed from available data).
Table 1 Adverse Reactions in Placebo-Controlled Trialsa
* Table: refer to manual
3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In the DECLARE clinical trial, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
In the DAPA-HF clinical trial, no serious adverse events of genital infection were reported in the dapagliflozin group and one case was reported in the placebo group. There were 7 patients (0.3%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In the DELIVER clinical trial, one serious adverse event of genital infection was reported in each group (<0.1%). There were 3 patients (0.1%) in the dapagliflozin group and no patients in the placebo group who discontinued treatment due to adverse events of genital infection.
In the DAPA-CKD clinical trial, serious adverse events of genital infection were reported in 3 cases (0.1%) in the dapagliflozin group and none in the placebo group. There were 3 patients (0.1%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In patients without diabetes, no serious adverse events of genital infection or adverse events leading to discontinuation of treatment were reported.
② Low blood sugar
The frequency of hypoglycemia in clinical trials in patients with diabetes depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. In a comprehensive analysis of safety information from 1,169 patients evaluated for dapagliflozin and saxagliptin combination therapy, the overall incidence of hypoglycemia was low at 24 weeks (≤1.8% in all groups).
In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in those receiving dapagliflozin 10 mg and glimepiride (6.0% and 7.9%, respectively) compared to those receiving placebo and glimepiride (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients at weeks 24 and 104, respectively, in patients administered dapagliflozin 10 mg in combination with insulin, and 0.5% were reported at weeks 24 and 104 in patients administered placebo in combination with insulin. Minor hypoglycemic episodes were reported in patients administered dapagliflozin 10 mg in combination with insulin. It was reported in 40.3% and 53.1% at weeks 24 and 104, respectively, and in patients receiving placebo with additional insulin, it was reported in 34.0% and 41.6%.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and in 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
The DECLARE trial showed that dapagliflozin therapy compared with placebo did not increase the risk of major hypoglycemic events. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and in 83 patients (1.0%) in the placebo group.
In the DAPA-HF clinical trial, major hypoglycemic events were reported in 4 patients (0.2%) each in the dapagliflozin and placebo groups, and occurred only in patients with type 2 diabetes. In the DELIVER clinical trial, major hypoglycemic events were reported in 6 patients (0.2%) in the dapagliflozin group and 7 patients (0.2%) in the placebo group. Major hypoglycemic events were observed only in patients with type 2 diabetes.
In the DAPA-CKD clinical trial, major hypoglycemic events were reported in 14 patients (0.7%) in the dapagliflozin group and 28 patients (1.3%) in the placebo group, and were observed only in patients with type 2 diabetes.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In the DECLARE clinical trial, the number of patients who developed adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2, 19 serious adverse events suggesting volume loss were reported in the dapagliflozin group and 13 cases in the placebo group.
In the DAPA-HF clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. The number of patients with serious adverse events suggesting volume loss was lower in the dapagliflozin group (23 patients [1.0%]) than in the placebo group (38 patients [1.6%]). Similar results were observed across subgroups including age, presence of diabetes at baseline, baseline eGFR, and systolic blood pressure. In the DELIVER clinical trial, the number of patients with serious adverse events suggesting a decrease in body fluid volume was 35 (1.1%) in the dapagliflozin group and 31 (1.0%) in the placebo group.
In the DAPA-CKD clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 120 (5.6%) in the dapagliflozin group and 84 (3.9%) in the placebo group. The number of patients with serious adverse events suggesting a decrease in body fluid volume was 16 (0.7%) in the dapagliflozin group and 15 (0.7%) in the placebo group.
④ Diabetic ketoacidosis
In the DECLARE clinical trial (median dapagliflozin exposure period of 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 cases in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients who developed diabetic ketoacidosis in the dapagliflozin group, 22 were taking insulin at the time the case occurred. Factors causing diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see ‘4. General precautions, 3) Ketoacidosis’).
In the DAPA-HF clinical trial, diabetic ketoacidosis cases were reported in 3 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group. In the DELIVER trial, diabetic ketoacidosis cases were reported in 2 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group.
In the DAPA-CKD clinical trial, no cases of diabetic ketoacidosis were reported in the dapagliflozin group and two cases of type 2 diabetes were reported in the placebo group.
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In the DECLARE clinical trial, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg group, which was less frequent than the 109 cases (1.3%) in the placebo group.
In the DAPA-HF clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was small, with no significant difference between the two groups: 14 patients (0.6%) in the dapagliflozin group and 17 patients (0.7%) in the placebo group. There were 5 patients (0.2%) in each of the dapagliflozin and placebo groups who discontinued treatment due to adverse events of urinary tract infection. In the DELIVER clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 41 (1.3%) in the dapagliflozin group and 37 (1.2%) in the placebo group. The number of patients who discontinued treatment due to adverse events of urinary tract infection was 13 (0.4%) in the dapagliflozin group and 9 (0.3%) in the placebo group.
In the DAPA-CKD clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 29 (1.3%) in the dapagliflozin group and 18 (0.8%) in the placebo group. There were 8 patients (0.4%) in the dapagliflozin group and 3 (0.1%) in the placebo group who discontinued treatment due to adverse events of urinary tract infection.
? Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. According to pooled safety data from 13 clinical trials, these adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal insufficiency (eGFR 60 mL/min/1.73m2 or higher), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse reactions were reported more frequently in patients with an eGFR greater than 30 mL/min/1.73m2 but less than 60 mL/min/1.73m2 (18.5% and 9.3% for dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In the DECLARE clinical trial, which included elderly patients and patients with renal impairment (eGFR less than 60 mL/min/1.73m2), eGFR decreased over time in both the dapagliflozin group and the placebo group. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.
In the DAPA-HF clinical trial and the DELIVER clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. In the DAPA-HF clinical trial, the initial decrease in average eGFR was -4.3 mL/min/1.73m2 in the dapagliflozin group and -1.1 mL/min/1.73m2 in the placebo group. At 20 months, the change from baseline in eGFR was similar between treatment groups (dapagliflozin group -5.3 mL/min/1.73m2, placebo group -4.5 mL/min/1.73m2). In the DELIVER clinical trial, the average decrease in eGFR at 1 month was -3.7 mL/min/1.73m2 in the dapagliflozin group and -0.4 mL/min/1.73m2 in the placebo group. The change from baseline in eGFR at 24 months was similar between treatment groups (dapagliflozin group -4.2 mL/min/1.73m2, placebo group -3.2 mL/min/1.73m2).
In the DAPA-CKD clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in average eGFR was -4.0 mL/min/1.73 m2 in the dapagliflozin group and -0.8 mL/min/1.73 m2 in the placebo group. The change from baseline in eGFR at 28 months was -7.4 mL/min/1.73m2 in the dapagliflozin group and -8.6 mL/min/1.73m2 in the placebo group.
⑦ Perineal gangrene (Fournier’s gangrene)
During post-marketing surveillance, cases of Fournier's gangrene have been reported in patients receiving SGLT2 inhibitors, including dapagliflozin (see 4. General precautions, 12) Perineal gangrene (Fournier's gangrene).
In the DECLARE clinical trial involving 17,160 patients with type 2 diabetes and a median exposure period of 48 months, a total of 6 cases of Fournier's gangrene were reported, including 1 case in the dapagliflozin group and 5 cases in the placebo group.
4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis (including diabetic ketoacidosis)
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
- Angioedema
5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,027 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.59% (805/3,027 people, total 1,122 cases) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
4. General precautions
1) Use for patients with hepatic impairment
Clinical trial experience in patients with hepatic impairment is limited. Dapagliflozin exposure is increased in patients with severe hepatic impairment.
2) Use in patients at risk of volume loss and/or hypotension
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients who may be at risk for drug-induced reductions in blood pressure, such as patients receiving antihypertensive treatment and a history of hypotension or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal disease), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte testing) is recommended. For patients exhibiting volume loss, temporary discontinuation of dapagliflozin is recommended until volume loss is restored.
3) Ketoacidosis
Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Ketoacidosis associated with this medicine may occur even when blood glucose is below 250 mg/dL. Patients treated with this medicine who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue this medicine, assess the patient’s condition and initiate treatment promptly.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement.
In many post-marketing reports, particularly in patients with type 1 diabetes, the presence or absence of ketoacidosis was not immediately identified and the introduction of treatment was delayed because the observed blood glucose levels were lower than those typically expected in diabetic ketoacidosis (most often less than 250 mg/dL). Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting treatment with this medication, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with this drug for the development of ketoacidosis, and consider temporarily discontinuing dapagliflozin administration if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.
Inform patients about the risk of diabetic ketoacidosis, its risk factors, signs and symptoms, and the fact that it may occur even when blood glucose is below 250 mg/dL. It is recommended that patients be able to monitor blood ketones and receive education on when monitoring is needed. Patients should seek prompt treatment if ketoacidosis is suspected.
4) Urosepsis and pyelonephritis
Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.
5) Reproductive infections (including fungi)
Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.
6) Elderly patients
Elderly patients are more likely to have renal impairment or be taking antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE-I) and type 1 angiotensin II receptor inhibitors (ARBs). The same recommendations regarding renal function apply to elderly patients as to all patients.
Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics.
From a pharmacokinetic perspective, there are insufficient data to make conclusions regarding blood drug exposure in patients over 70 years of age.
7) Urine laboratory evaluation
Patients receiving this drug will test positive for urinary glucose due to its mechanism of action.
8) Use of drugs known to cause hypoglycemia
Insulin secretagogues such as insulin and sulfonylureas cause hypoglycemia. Therefore, when used in combination with this drug, the dose of insulin or insulin secretagogue may need to be reduced to reduce the risk of hypoglycemia.
9) SGLT2 inhibitors such as this drug may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine output. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.
10) Weight loss
In a 24-week, placebo-controlled study of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes, the change in body weight from baseline was −3.16 kg with dapagliflozin and −2.19 kg with placebo, indicating greater weight loss with dapagliflozin.
11) Lower limb amputation
In long-term clinical studies of other SGLT2 inhibitors in patients with type 2 diabetes, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. It is important to discuss routine preventive foot care with patients with diabetes.
12) Perineal gangrene (Fournier’s gangrene)
In post-marketing surveillance of diabetic patients taking SGLT2 inhibitors, although rare, severe, life-threatening perineal gangrene requiring prompt surgical intervention was reported (see 3. Adverse Reactions, 3) Description of Specific Adverse Reactions, ⑦ Perineal Gangrene (Fournier's Gangrene)). Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving this drug develops pain, maceration, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. Administration of dapagliflozin should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.
5. Drug interactions
1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylurea can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.
2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.
3) Effect of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.
4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor serum lithium levels.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.
5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.
6) Pediatric
Interaction studies were conducted only in adults.
7) Interference with 1,5-anhydroglucitol test
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.
6. Administration to pregnant and lactating women
1) Pregnant women
There are no data on dapagliflozin administered to pregnant women. Studies on rats showed toxicity to kidney development during the second and third trimesters of human pregnancy. The use of dapagliflozin in pregnant women is not recommended. Once pregnancy is confirmed, dapagliflozin administration should be discontinued.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
2) Nursing mothers
It is not known whether dapagliflozin and its metabolites are passed into human milk. Pharmacodynamic/toxicological data in animals indicate excretion of dapagliflozin/metabolite in milk and pharmacologically mediated effects in nursing offspring. Risk to neonates/infants cannot be excluded. Dapagliflozin should not be used during breastfeeding.
7. Administration to children
The safety and efficacy of dapagliflozin in pediatric patients have not been established.
8. Treatment in case of overdose
Dapagliflozin did not show any toxicity at single oral doses of up to 500 mg (50 times the maximum recommended human dose) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In a clinical trial in which healthy subjects and patients with type 2 diabetes were administered up to 100 mg (10 times the maximum recommended human dose) once daily for 2 weeks, the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.
9. Application precautions
Dapagliflozin has no or little effect on the ability to drive or use machines. Patients should be aware of the risk of hypoglycemia when administering dapagliflozin in combination with sulfonylurea or insulin.
10. Precautions for storage and handling
1) Store out of reach of children.
2) It is not advisable to change the container as it may damage the quality of the product or cause an accident. Store in original container.
11. Information for experts
1) Mechanism of action: Dapagliflozin is a very potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose-cotransporter 2 (SGLT2). Inhibition of SGLT2 by dapagliflozin reduces the reabsorption of glucose from the glomerular filtrate in the proximal renal tubules and simultaneously reduces sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis. Therefore, dapagliflozin increases the delivery of sodium to the distal tubule, which increases the tubuloglomerular feedback and reduces intraglomerular pressure. This, together with osmotic diuresis, results in reduced volume overload, decreased blood pressure, and lower preload and afterload, which may have beneficial effects on cardiac remodeling and diastolic function and preserve renal function. Other effects include increased hematocrit and weight loss.
The heart and kidney benefits of dapagliflozin do not depend solely on its hypoglycemic effects and are not limited to patients with diabetes.
Dapagliflozin reduces glucose reabsorption in the kidneys, resulting in urinary glucose excretion, thereby improving fasting and postprandial plasma glucose levels. This glucose excretion is observed upon the first administration of the drug and is maintained throughout the 24-hour dosing interval and continues throughout the treatment period. The amount of glucose eliminated by the kidneys through this mechanism is dependent on blood glucose concentration and GFR. Accordingly, the amount of glucose that is filtered is small and is reabsorbed by the SGLT1 transporter and unblocked SGLT2, so dapagliflozin appears to have a low tendency to cause hypoglycemia in subjects with normal blood sugar and/or low eGFR. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycemia. The action of dapagliflozin is unrelated to insulin secretion and action. Improvements in homeostatic model assessments of beta cell (HOMA beta cell) function were observed in clinical trials of dapagliflozin.
SGLT2 is selectively expressed in the kidney. Dapagliflozin does not inhibit other glucose transporters important for glucose transport to peripheral tissues and is more than 1,400-fold selective for SGLT2 compared to SGLT1, the main transporter responsible for glucose absorption in the digestive tract.
2) Pharmacokinetic information:
① Absorption: Dapagliflozin is rapidly absorbed after oral administration. The highest concentration of dapagliflozin in the blood (Cmax) was generally achieved within 2 hours when administered on an empty stomach. Cmax and AUC increase proportionally with dapagliflozin dose. When administered orally at 10 mg, the bioavailability of dapagliflozin was 78%, and when administered with a high-fat diet, the Cmax of dapagliflozin was reduced by up to 50% compared to fasting, Tmax was delayed by about 1 hour, and AUC was unchanged. This difference is not considered to have clinical significance.
② Distribution: The protein binding rate of dapagliflozin is approximately 91% and does not vary depending on the disease state (e.g. renal or hepatic impairment, etc.).
③ Metabolism: Dapagliflozin is extensively metabolized and mainly produces dapagliflozin 3-O-glucuronide, an inactive metabolite. Dapagliflozin 3-O-glucuronide or other metabolites do not contribute to the hypoglycemic effect. The mediator that forms dapagliflozin 3-O-glucuronide is UGT1A9, an enzyme found in the liver and kidneys, and CYP-mediated metabolism accounts for a small percentage of the metabolic pathways in the human body.
④ Excretion: The terminal elimination half-life (t1/2) of dapagliflozin was 12.9 hours, and the systemic clearance rate after administration of dapagliflozin was 207ml/min. Dapagliflozin and related metabolites are mainly excreted through urine, of which less than 2% is unmetabolized. When 50 mg of 14C-dapagliflozin was administered, a total of 96% was recovered, including 75% from urine and 21% from feces. In feces, approximately 15% of the dose was in unmetabolized form.
⑤ Renal impairment: In steady state (20 mg once daily, dapagliflozin administered for 7 days), the average body exposure to dapagliflozin was 32%, 60%, and 87% higher in test subjects with type 2 diabetes and mild, moderate, or severe renal dysfunction (measured by plasma clearance of iohexol) compared to type 2 diabetic patients with normal renal function. During 24 hours at steady state, urinary glucose excretion was very dependent on the state of renal function and was 85, 52, 18, and 11 g (glucose/day) in subjects with normal renal function, mild, moderate, and severe renal impairment, respectively. The effect of hemodialysis on dapagliflozin exposure is unknown. The effect of renal function decline on systemic exposure was evaluated using a population pharmacokinetic model. Consistent with previous results, the predicted AUC of this model was higher in patients with chronic kidney disease than in patients with normal renal function, and was not significantly different in patients with chronic kidney disease with or without type 2 diabetes.
⑥ Hepatic impairment: In subjects with mild or moderate hepatic impairment (Child-Pugh Class A, B), the Cmax and AUC of dapagliflozin were 12% and 36% higher, respectively, compared to subjects with normal liver function. This is not judged to be a clinically significant difference. In subjects with severe hepatic impairment (Child-Pugh Class C), the mean Cmax and AUC of dapagliflozin were 40% and 67% higher, respectively, compared to subjects with normal liver function.
3) Clinical trial information
To evaluate the blood sugar-lowering effectiveness and safety of dapagliflozin, 13 double-blind, randomized, controlled clinical trials were conducted on 6,362 type 2 diabetes patients, of which 4,273 received dapagliflozin. Twelve studies had a treatment period of 24 weeks, and eight of these were extended to long-term trials with an additional treatment period of 24 to 80 weeks (up to 104 weeks). One trial was a 52-week trial and was extended to 52 and 104 weeks. Additionally, two 24-week double-blind, randomized, controlled clinical trials were conducted to evaluate the efficacy and safety of the combined administration of saxagliptin and dapagliflozin in 854 patients with type 2 diabetes.
To evaluate the effect of dapagliflozin 10 mg compared to placebo on cardiovascular and kidney-related events, a clinical trial (DECLARE) was conducted in 17,160 patients with type 2 diabetes with confirmed cardiovascular disease or cardiovascular risk factors.
Monotherapy
A 24-week, double-blind, randomized, placebo-controlled study, followed by an extension, evaluated the efficacy and safety of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes. Once-daily dapagliflozin produced a statistically significant reduction in glycated hemoglobin (HbA1c) compared with placebo (p < 0.0001; see Table 2).
In an additional extension study, the HbA1c reduction was maintained at week 102 (adjusted mean reduction from baseline: -0.61% and -0.17% for dapagliflozin 10 mg and placebo, respectively).
Table 2 Outcomes at 24 weeks (LOCFa) in a placebo-controlled study of dapagliflozin monotherapy in patients with inadequate glycemic control
* Table: refer to manual
Combination therapy with other hypoglycemic agents
Initial combination therapy with metformin
Two 24-week active-controlled studies were conducted to evaluate the efficacy and safety of initial combined administration of dapagliflozin and extended-release metformin in patients with type 2 diabetes who had no prior drug treatment. When dapagliflozin 10 mg and metformin were administered together, HbA1c was significantly reduced compared to each administration alone (see Table 3).
Table 3 Outcomes at 24 weeks in an active-controlled study of initial combination therapy with dapagliflozin and extended-release metformin in drug-naïve patients (LOCFa)
* Table: refer to manual
An active-controlled trial comparing dapagliflozin plus the addition of a sulfonylurea (glipizide) in patients with inadequate glycemic control on metformin.
A 52-week active control non-inferiority study (52 weeks and 104 weeks extension) was conducted to compare and evaluate the additional use of dapagliflozin and sulfonylurea (glipizide) to metformin in patients with type 2 diabetes who had insufficient glycemic control with metformin (HbA1c greater than 6.5% but less than 10%). As a result, dapagliflozin demonstrated non-inferiority by showing a similar reduction in HbA1c compared to baseline at 52 weeks as glipizide (see Table 4). At week 104, the reduction in HbA1c compared to baseline was -0.32% for dapagliflozin and -0.14% for glipizide. The incidence of one or more hypoglycemic events was significantly lower in the dapagliflozin group (3.5% and 4.3% for 52 and 104 weeks, respectively) than in the glipizide group (40.8% and 47.0% for 52 and 104 weeks, respectively).
Table 4 Outcomes at Week 52 (LOCFa) in an active-controlled study comparing dapagliflozin plus each additional sulfonylurea (glipizide) in patients with inadequate glycemic control on metformin
* Table: refer to manual
Additional combination therapy with other hypoglycemic agents
Dapagliflozin includes metformin (see Table 5), sulfonylurea (glimepiride; see Table 6), insulin (alone or in combination with oral hypoglycemic agents; see Table 7), sitagliptin (alone or in combination with metformin; see Table 8), metformin and sulfonylurea (see Table 9), metformin and saxagliptin (see Table 10), and pioglitazone. When administered in combination with (see Table 11), there was a statistically significant decrease in HbA1c compared to placebo at 24 weeks (p <0.0001).
In a trial in which dapagliflozin was added to metformin, the HbA1c reduction effect was maintained even at 102 weeks. The HbA1c reduction effect was maintained even when the test using the drug in combination with glimepiride was extended to 48 weeks, and the study using the drug in combination with insulin was extended to 104 weeks.
Table 5 Outcomes at 24 weeks (LOCFa) in a placebo-controlled study comparing the addition of dapagliflozin in patients with inadequate glycemic control on metformin monotherapy
* Table: refer to manual
Table 6 Outcomes at 24 weeks (LOCFa) in a placebo-controlled study comparing the addition of dapagliflozin in patients with inadequate glycemic control on sulfonylurea (glimepiride) monotherapy (LOCFa)
* Table: refer to manual
Table 7 Placebo-controlled study comparing add-on dapagliflozin in patients with inadequate glycemic control with insulin (alone or in combination with oral hypoglycemic agents), outcomes at 24 weeks (LOCFa)
* Table: refer to manual
Table 8 Outcomes at Week 24 (LOCFa) in a placebo-controlled study comparing the add-on of dapagliflozin in patients with inadequate glycemic control with sitagliptin (alone or in combination with metformin)
* Table: refer to manual
Table 9 Results at Week 24 in a Placebo-Controlled Study Comparing the Add-On of Dapagliflozin in Patients with Inadequate Glycemic Control on Metformin and Sulfonylureas
* Table: refer to manual
Table 10 Results at Week 24 in a Placebo-Controlled Study Comparing the Add-On of Dapagliflozin in Patients with Inadequate Glycemic Control with Saxagliptin and Metformin
* Table: refer to manual
Table 11 Outcomes at Week 24 (LOCFa) in a Placebo-Controlled Study Comparing the Add-On of Dapagliflozin in Patients with Inadequate Glycemic Control with Pioglitazone
* Table: refer to manual
Patients with moderate renal impairment stage 3A (eGFR 45-60mL/min/1.73m2)
In a study limited to diabetic patients with an eGFR of 45 to 60 mL/min/1.73 m2, the effectiveness of additional administration of dapagliflozin was evaluated in patients whose glycemic control was inadequate with existing therapy. Dapagliflozin showed a decrease in HbA1c as shown in Table 12 compared to placebo.
Table 12 Results at 24 weeks in a placebo-controlled study confirming the effect of dapagliflozin in diabetic patients with eGFR 45-60mL/min/1.73m2
* Table: refer to manual
fasting blood sugar
When dapagliflozin 10 mg was administered alone or in combination with metformin, glimepiride, metformin and sulfonylurea, sitagliptin (alone or in combination with metformin), saxagliptin and metformin or insulin, it statistically significantly reduced fasting blood sugar compared to placebo. This effect was maintained throughout the trial, which extended from the first week of administration to 104 weeks.
In a study limited to diabetic patients with an eGFR of 45 to 60 mL/min/1.73 m2, the fasting blood sugar value at 24 weeks of administration was -0.27 mmol/L (-4.87 mg/dL) for placebo and -1.19 mmol/L (-21.46 mg/dL) for dapagliflozin.
postprandial blood sugar
When dapagliflozin 10 mg was administered in combination with glimepiride or sitagliptin (alone or in combination with metformin), a decrease in 2-hour postprandial blood glucose was observed at 24 weeks and maintained until 48 weeks.
Effects on the cardiovascular system and kidneys
The DECLARE study was a multinational, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted to determine the effects of dapagliflozin compared to placebo on the cardiovascular system and kidneys when added to existing treatment regimens. In addition to type 2 diabetes, all patients had at least two cardiovascular risk factors (men over 55 years of age or women over 60 years of age, at least one of dyslipidemia, hypertension, or current smoking) or had cardiovascular disease.
Among the 17,160 patients, 6,974 (40.6%) had cardiovascular disease and 10,186 (59.4%) did not have cardiovascular disease. 8,582 people were randomly assigned to receive dapagliflozin 10 mg and 8,578 were randomly assigned to placebo. The median follow-up period was 4.2 years.
The average age of the group participating in the study was 63.9 years, of which 37.4% were women. The average duration of diabetes for all patients was 11.9 years, and 22.4% had diabetes for less than 5 years. The average HbA1c was 8.3% and the average body mass index was 32.1 kg/m2.
At baseline, 10.0% of patients had a history of heart failure. The average eGFR was 85.2 mL/min/1.73m2. 7.4% of patients had an eGFR less than 60 mL/min/1.73m2, and 30.3% of patients had microalbuminuria [urinary albumin-to-creatinine ratio (UACR) of 30 mg/g or more - 300 mg/g or less] or macroalbuminuria (UACR of 300 mg/g). There was an excess).
Most patients (98%) were receiving at least one medicine for diabetes at baseline: 82% were taking metformin, 41% insulin and 43% a sulfonylurea.
Approximately 81.3% of patients received an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 75.0% a statin, 61.1% an antiplatelet agent, 55.5% aspirin, 52.6% a beta-blocker, 34.9% a calcium channel blocker, 22.0% a thiazide diuretic and 10.5% a loop diuretic.
Major cardiovascular events
Dapagliflozin 10 mg demonstrated non-inferiority to placebo for the composite endpoint of adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke (one-sided p<0.001).
Hospitalization due to heart failure or death from cardiovascular disease
Dapagliflozin 10 mg was superior to placebo for the primary composite endpoint of preventing hospitalization for heart failure or cardiovascular death (Figure 1).
In an exploratory analysis of each factor, a significant decrease in the incidence of hospitalization due to heart failure contributed to the difference in treatment effect, and there was no significant difference in cardiovascular disease mortality.
The treatment benefit of dapagliflozin compared to placebo was observed regardless of baseline cardiovascular disease and underlying heart failure, and was consistent across key subgroups including age, gender, renal function (eGFR), and region.
Figure 1. Time to first hospitalization for heart failure or death from cardiovascular disease.
* Figure 1: Refer to manual
Number of patients: patients at risk at the beginning of each interval
nephropathy
Height-related endpoints were evaluated for exploratory purposes.
Dapagliflozin reduced the incidence of multiple events, including confirmed persistent eGFR decline, end-stage renal disease, and renal or cardiovascular death. Differences between treatment groups were seen in the reduction of renal events, including persistent eGFR decline, end-stage renal disease, and kidney-related death.
The hazard ratio (HR) for dapagliflozin compared with placebo for time to nephropathy event (persistent eGFR decline, end-stage renal disease, or kidney-related death) was 0.53 [95% CI 0.43, 0.66].
In patients without a history of albuminuria, dapagliflozin reduced the new onset of persistent albuminuria (UACR > 30 mg/g) compared to placebo (hazard ratio (HR) 0.79 [95% CI 0.72, 0.87]), and in patients with a history of macroalbuminuria, the reduction in macroalbuminuria was greater in the dapagliflozin group than in the placebo group (hazard ratio (HR) 1.82 [95% CI 1.51, 2.20]).
chronic heart failure
DAPA-HF clinical trial: left ventricular ejection fraction ≤40% (LVEF≤40%) heart failure
DAPA-HF was a multinational, multicenter, randomized, double-blind, placebo-controlled study that evaluated the effect of dapagliflozin compared to placebo on the incidence of cardiovascular death and worsening of heart failure when added to standard treatment in patients with heart failure (NYHA functional class II to IV) with reduced left ventricular systolic function (left ventricular ejection fraction [LVEF] 40% or less).
Among 4,744 patients, 2,373 were randomly assigned to dapagliflozin 10 mg and 2,371 to placebo and were treated for a median of 18 months. The average age of the test group was 66 years, and 77% were male.
At baseline, 67.5% of patients were NYHA class II, 31.6% were class III, and 0.9% were class IV, median LVEF was 32%, 56% of heart failure was ischemic, 36% was non-ischemic, and 8% had unknown etiology. 42% of patients in each treatment group had a history of type 2 diabetes, and an additional 3% of patients in each group were classified as having type 2 diabetes based on the criteria of HbA1c ≥ 6.5% applied at the time of subject registration and randomization. 94% of patients were being treated with ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors (ARNI; 11%), 96% with beta-blockers, 71% with mineralocorticoid receptor antagonists, 93% with diuretics, and 26% had an implanted device with defibrillator function.
Patients with an eGFR of 30 mL/min/1.73 m2 or higher at the time of recruitment were included in the study. The average eGFR was 66 mL/min/1.73 m2, 41% of patients had eGFR less than 60 mL/min/1.73 m2, and 15% had eGFR less than 45 mL/min/1.73 m2.
Death from cardiovascular disease and worsening heart failure
Dapagliflozin reduced the incidence of the primary composite endpoint of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure (HR 0.74 [95% CI 0.65, 0.85], p < 0.0001).
The event curves for dapagliflozin and placebo initially spaced out and continued throughout the trial (Figure 2).
Figure 2 Time to first composite event of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure.
* Figure 2: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
Number of patients: patients at risk at the beginning of each interval
Each of the three components comprising the primary composite endpoint all indicated treatment effectiveness. Emergency hospital visits due to heart failure were reduced (Figure 3).
Figure 3 Treatment effect on primary endpoints and components and all-cause mortality.
* Figure 3: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up.
The p-values for each component and for all-cause mortality are nominal.
Dapagliflozin also reduced the total number of hospitalizations for heart failure (first-episode and recurrent) and cardiovascular disease deaths; There were 567 cases in the dapagliflozin group and 742 cases in the placebo group (rate ratio (RR) 0.75 [95% CI 0.65, 0.88]; p = 0.0002).
The therapeutic benefit of dapagliflozin was shown in both heart failure patients with type 2 diabetes and heart failure patients without diabetes.
Dapagliflozin reduced the incidence of the primary composite endpoint by HR 0.75 [95% CI 0.63, 0.90] in patients with diabetes and by HR 0.73 [95% CI 0.60, 0.88] in patients without diabetes.
Additionally, the treatment benefit of dapagliflozin compared to placebo for the primary endpoint was consistent across key subgroups, including heart failure combination therapy, renal function (eGFR), age, gender, and region.
DELIVER clinical trial: Heart failure with left ventricular ejection fraction >40% (LVEF>40%)
DELIVER was a multinational, multicenter, randomized, double-blind, placebo-controlled study that evaluated the effect of dapagliflozin compared to placebo on the incidence of cardiovascular death and worsening heart failure when added to standard treatment in patients aged 40 years or older with heart failure (NYHA functional class II to IV) with LVEF greater than 40%.
Among 6,263 patients, 3,131 were randomly assigned to dapagliflozin 10 mg and 3,132 to placebo and were treated for a median of 28 months. The trial includes 654 (10%) patients with subacute heart failure (defined as patients randomized during hospitalization for heart failure or within 30 days of discharge).
The average age of the test population was 72 years, 56% were male, 71% were white, 3% were black or African American, and 20% were Asian.
At baseline, 75% of patients were NYHA class II, 24% were class III, and 0.3% were class IV, and the median LVEF was 54%. 34% of patients had LVEF 49% or less, 36% of patients had LVEF 50-59%, and 30% had LVEF 60% or more. In each treatment group, 45% had a history of type 2 diabetes. Concomitant medications included ACE inhibitors/ARBs/ARNIs (77%), beta-blockers (83%), diuretics (98%), and mineralocorticoid receptor antagonists (43%).
Patients with an eGFR of 25 mL/min/1.73 m2 or higher at the time of recruitment were included in the study. The average eGFR was 61 mL/min/1.73 m2, 49% of patients had an eGFR less than 60 mL/min/1.73 m2, 23% had an eGFR less than 45 mL/min/1.73 m2, and 3% had an eGFR less than 30 mL/min/1.73 m2.
Death from cardiovascular disease and worsening heart failure
Dapagliflozin was superior to placebo in the primary composite endpoint, reduction in the incidence of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure (HR 0.82 [95% CI 0.73, 0.92], p=0.0008). The event curves were initially separated for dapagliflozin and placebo and this separation was maintained throughout the trial (Figure 4).
Figure 4 Time to first composite event of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure.
* Figure 4: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
Number of patients: patients at risk at the beginning of each interval
The treatment effect on the primary composite endpoint and its components is shown in Figure 5.
Figure 5 Treatment effects on primary composite endpoints and components
* Figure 5: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up.
The p-value for each component is nominal. Cardiovascular disease mortality, a component of the primary endpoint, was tested as a secondary endpoint under formal Type I error control.
Dapagliflozin was superior to placebo in reducing the total number of heart failure exacerbation events (first hospitalization and readmission for heart failure or emergency hospital visit for heart failure) and cardiovascular deaths; There were 815 cases in the dapagliflozin group and 1,057 cases in the placebo group (incidence rate ratio 0.77 [95% CI 0.67, 0.89]; p=0.0003).
The treatment benefit of dapagliflozin compared to placebo for the primary endpoint was observed in all subgroups: patients with LVEF ≤49%, patients with LVEF 50-59%, and patients with LVEF ≥60%. The effect was consistent in other major subgroups (age, gender, NYHA class, NT-proBNP level, subacute status, type 2 diabetes, renal function (eGFR), etc.).
chronic kidney disease
DAPA-CKD is a multinational, multicenter, event-based study comparing dapagliflozin to placebo when added to background standard therapy in patients with chronic kidney disease (CKD) with eGFR ≥25 mL/min/1.73 m2 but ≤75 mL/min/1.73 m2 and albuminuria (urinary albumin creatinine ratio [UACR] ≥200 mg/g but ≤5,000 mg/g). This was a randomized, double-blind, parallel group, placebo-controlled trial. The primary objective was to measure the effectiveness of dapagliflozin compared to placebo in reducing the composite endpoint of reduction in sustained eGFR greater than 50%, end-stage kidney disease (ESKD) (defined as sustained eGFR less than 15 mL/min/1.73 m2, chronic dialysis treatment, or receiving a kidney transplant), CV death, or kidney-related death.
The trial excluded patients with autosomal dominant or recessive polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and patients who had received cytotoxic treatment, immunosuppression, or immunomodulatory therapy within the previous 6 months.
A total of 4,304 patients were randomized to dapagliflozin 10 mg once daily (N = 2,152) or placebo (N = 2,152) and followed for a median of 28.5 months. Treatment continued during the study even if eGFR fell to 25 mL/min/1.73 m² or below.
At baseline, the mean eGFR was 43.1 mL/min/1.73 m2 and the median UACR was 949.3 mg/g; 44.1% of patients had an eGFR between 30 mL/min/1.73 m2 and less than 45 mL/min/1.73 m2, and 14.5% had an eGFR less than 30 mL/min/1.73 m2. 67.5% of these patients had type 2 diabetes.
Patients were receiving standard therapy: 97.0% were treated with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB). Approximately 44% were taking an antiplatelet agent and 65% a statin.
The average age of the test population was 61.8 years, 66.9% were male, 53.2% were white, 4.4% were black or African American, and 34.1% were Asian.
Dapagliflozin was superior to placebo in reducing the primary composite endpoint of sustained decline in eGFR greater than 50%, leading to ESKD, CV death, or kidney-related death (HR 0.61 [95% CI 0.51, 0.72], p<0.0001). The number of patients requiring treatment per 27 months was 19 (95% CI 15, 27). Based on Kaplan-Meier plots, the event curves for dapagliflozin and placebo began to diverge early (month 4) and continued to diverge throughout the study period (Figure 6).
Figure 6 Primary composite endpoint: Time to first occurrence of sustained decline in eGFR greater than 50%, ESKD, CV death, or kidney-related death.
* Figure 6: Refer to manual
Number of patients: patients at risk at the beginning of each interval
All four components of the primary composite endpoint individually contributed to this treatment effect (Figure 7). Dapagliflozin was associated with the composite endpoint of decreased eGFR >50% sustained, ESKD or kidney-related death (HR 0.56 [95% CI 0.45, 0.68], p<0.0001), composite endpoint of CV death and hospitalization for heart failure (HR 0.71 [95% CI 0.55, 0.92], p=0.0089), and all-cause mortality. It also reduced the incidence of death (HR 0.69 [95% CI 0.53, 0.88], p=0.0035).
Figure 7 Treatment effect related to primary and secondary composite endpoints, their individual components, and all-cause mortality
* Figure 7: Refer to manual
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up.
Risk ratio estimates are not presented for subgroups with a total of less than 15 cases for both groups combined.
The p-value for the components of a composite endpoint is a nominal value.
The therapeutic effect of dapagliflozin was consistent in patients with chronic kidney disease with type 2 diabetes and in patients with chronic kidney disease without diabetes (Figure 8).
Figure 8 Treatment effect in patients with type 2 diabetes and in patients without diabetes
* Figure 8: Refer to manual
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added. Risk ratio estimates are not presented for subgroups with a total of less than 15 cases for both groups combined.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up. The p-value is a nominal value.
The treatment benefit of dapagliflozin compared to placebo with respect to the primary composite endpoint was consistent across key subgroups (Figure 9).
Figure 9 Treatment effect related to primary composite endpoint by subgroup
* Figure 9: Refer to manual
n/N# Number of subjects with events/Number of subjects in subgroup
The treatment benefit of dapagliflozin was also observed for exploratory endpoints:
? A greater reduction in UACR was demonstrated with dapagliflozin compared to placebo. These effects were observed as early as day 14 and were maintained throughout the trial. The adjusted mean percent change from baseline in UACR (mg/g) at month 36 was -41% in patients treated with dapagliflozin and -20% in patients treated with placebo, with a difference between treatment groups of -26.3% ([95% CI -36.8, -14.0], nominal p=0.0001).
? The incidence of serum creatinine doubling (a measure of acute worsening of renal function) from the most recent laboratory measurement was reduced in dapagliflozin compared with placebo (HR 0.68 [95% CI 0.49, 0.94], nominal p=0.0187).
4) Non-clinical safety data
① Carcinogenicity: Dapagliflozin did not induce tumors in mice or rats at any of the doses evaluated in the 2-year carcinogenicity study. The oral doses in mice were 5, 15, and 40 mg/kg/day for males and 2, 10, and 20 mg/kg/day for females, and the oral doses for rats were 0.5, 2, and 10 mg/kg/day for both sexes. The highest dose evaluated in mice corresponded to an AUC exposure multiple of approximately 72 (males) and 105 (female) the human AUC at the maximum recommended human dose (MRHD) of 10 mg per day. The AUC exposure in rats was approximately 131 times (males) and 186 times (females) the human AUC at MRHD.
② Mutagenicity: Dapagliflozin was negative in the Ames mutagenicity test and positive in the in vitro chromosomal abnormality test, but this was true when the concentration was over 100 mg/mL under S9 activity conditions. In particular, dapagliflozin was negative for chromosomal abnormalities in in vivo conditions in micronucleus or DNA repair tests conducted on rats at an exposure equivalent to more than 2,100 times the human exposure in MRHD. These studies support that dapagliflozin does not present a genotoxic risk to humans, given the absence of neoplastic findings in rat and mouse carcinogenicity studies.
③ Reproductive dysfunction: In fertility and early embryo development tests on rats, 15, 75, or 300/210 mg/kg/day of dapagliflozin was administered to males (300 mg/kg/day dose was reduced to 210 mg/kg/day after 4 days), and 3, 15, or 75 mg/kg/day doses were administered to females. Dapagliflozin did not affect mating, fertility, or early embryonic development in males or females at any dose administered (fold exposure ≤1708 and 998 times the MRHD in males and females). However, at 300/210 mg/kg/day, seminal vesicle and epididymal weight decreased, sperm motility and sperm count decreased, and the number of morphologically abnormal sperm was low.
④ Teratogenicity: Direct administration to young rats during the weaning period and indirect exposure to the drug during the second half of pregnancy and lactation (the period corresponding to the second and third trimesters of pregnancy in relation to human kidney development) are associated with an increase in the severity and incidence of renal pelvis dilatation and tubular dilatation in offspring. In a toxicity study in young animals, when dapagliflozin was administered to young rats on the 21st day of life at doses of 1, 15, or 75 mg/kg/day for up to 90 days, renal pelvis dilatation and tubular dilatation were reported at all doses; Exposure to offspring at the lowest dose was more than 15 times the MRHD. These observations were associated with a dose-related increase in kidney mass and macroscopic renal hypertrophy at all doses. The renal pelvis and tubular dilatation observed in young animals were not completely reversed during a recovery period of approximately 1 month.
⑤ Early developmental disorders: In a separate study on prenatal and postnatal development, maternal rats were administered drugs (1, 15, or 75 mg/kg/day) from the 6th day of pregnancy to the 21st day after birth, and the offspring were exposed indirectly through uterus and breastfeeding. (A separate study was conducted to evaluate the effects of dapagliflozin on milk and offspring.) Increased severity or events of renal pelvic dilatation were again observed in adult offspring of dams receiving the dose, albeit only at a dose of 75 mg/kg/day (corresponding to maternal and offspring dapagliflozin exposures of 1415 and 137 times [human levels in MRHD], respectively). Additional developmental toxicity was limited to dose-related reductions in pup body weight, which were observed at doses above 15 mg/kg/day (pup exposure greater than 29 times [human levels in MRHD]). Maternal toxicity was evident only at 75 mg/kg/day and was limited to a transient decrease in body weight and food consumption at the beginning of administration. The NOAEL for developmental toxicity, 1 mg/kg/day, is approximately 19 times the [human level in MRHD] and corresponds to maternal systemic exposure.
In additional embryo-fetal development studies in rats and rabbits, dapagliflozin was administered at intervals corresponding to key periods of organogenesis in each species. No maternal or developmental toxicity was observed in rabbits at any dose administered (20, 60, or 180 mg/kg/day); 180 mg/kg/day corresponds to a systemic exposure approximately 1191 times the MRHD. In rats, dapagliflozin was not embryonic lethal or teratogenic up to a dose of 75 mg/kg/day (approximately 1441 times the MRHD). Maternal and developmental toxicity was associated at a dose of 150 mg/kg/day (approximately 2344 times [human level in MRHD]). Maternal toxicity includes mortality, abnormal clinical signs, and reduction in body weight and food consumption. Developmental toxicities include embryo-fetal mortality, increased fetal malformations and skeletal dysmorphic events, and reduced fetal weight. The malformations are macrovascular malformation, costal and central spinal fusion, and sternum and central sternal duplication. The variation was mainly reduced ossification.
⑥ Animal toxicology: Most effects observed in major repeated-dose toxicity tests on rats and dogs were judged to be accompanied by pharmacologically mediated increases in urinary glucose, and included weight loss and/or decreased body weight gain rate, increased feed consumption, and increased urine volume due to osmotic diuretics. Dapagliflozin was well tolerated when administered orally to rats at a dose of 25 mg/kg/day (more than 346 times the human exposure at MRHD) for up to 6 months and to dogs at a dose of 120 mg/kg/day (more than 3200 times the human exposure at MRHD) for up to 12 months. In addition, as a result of a single-dose test of dapagliflozin, in both rat and dog toxicity tests, dapagliflozin 3-O-glucuronide metabolites were formed at an exposure level (AUC) equivalent to or higher than the expected human dapagliflozin 3-O-glucuronide exposure after administration of dapagliflozin in MRHD. The most notable nonclinical toxicological findings in rats, increased cancellous bone and tissue mineralization (related to increased serum calcium), were observed only at high exposure multiples (>2100-fold based on human exposure at MRHD). Despite reaching an exposure multiple of more than 3200 times the human exposure at MRHD, there were no dose limitations or target organ toxicities in the 12-month dog study.
5) Pharmaceutical equivalence test information
A. A randomized, open-label, two-treatment, two-sequence, two-period crossover study compared the test product, Dapazin 10 mg tablets (dapagliflozin bis-L-proline; KyungDong Pharm Co., Ltd.), with the reference product, Forxiga 10 mg tablets (dapagliflozin propanediol monohydrate; AstraZeneca Korea). Thirty-five healthy adults received a single oral dose under fasting conditions, and plasma dapagliflozin concentrations were measured. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating equivalence.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Dapagliflozin bis L-proline (in-house specification) ----- 7.815mg (5mg as dapagliflozin)
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry II yellow (85F92582), silicon dioxide, low-substituted hydroxypropyl cellulose
2. Effectiveness
1. Type 2 diabetes: This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
- monotherapy
- Combination therapy
For the effect on cardiovascular events in patients with inadequately controlled type 2 diabetes and established cardiovascular disease or cardiovascular risk factors, see “Precautions for Use, 11. Information for Healthcare Professionals, 3) Clinical Study Information.”
2. Chronic heart failure: Reduces the risk of death due to cardiovascular disease, hospitalization due to heart failure, and emergency hospital visit due to heart failure in patients with chronic heart failure (NYHA class II-IV).
This drug is administered in combination with other standard heart failure treatments.
3. Chronic kidney disease: In patients with chronic kidney disease, the estimated glomerular filtration rate (eGFR) continues to decline, reaching end-stage renal disease, and reducing the risk of death from cardiovascular disease and kidney-related death.
This drug is administered in combination with other standard treatments for kidney disease.
3. Dosage and dosage
type 2 diabetes
Monotherapy and additional combination therapy
The recommended dose of this drug is 10 mg once daily for monotherapy and additional combination therapy with other hypoglycemic agents such as insulin. If this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycemia.
Early combination therapy
When co-administered with metformin in those who have not previously received diabetes medication, the initial recommended dose of this drug is 5 mg once daily or 10 mg once daily.
Chronic heart failure and chronic kidney disease
The recommended dose of this drug is 10 mg once a day.
special group
renal impairment
- eGFR less than 45 mL/min/1.73m2: It is not recommended to administer this drug to improve glycemic control.
- eGFR less than 25 mL/min/1.73m2: It is not recommended to start treatment with this drug in patients with chronic heart failure and chronic kidney disease.
-Patients on dialysis: Do not administer this drug.
liver failure
No dose adjustment is necessary for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10 mg.
Elderly (≥ 65 years): Dosage adjustment based on age is not recommended.
Children: The effectiveness and safety of dapagliflozin in children under 18 years of age have not been established. There is no relevant data.
Method of administration: This drug can be administered orally, once a day, at any time of the day, regardless of food intake. Tablets should be swallowed whole.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with a history of hypersensitivity to the main ingredients or excipients of this drug
2) Patients with type 1 diabetes or diabetic ketoacidosis
3) This medicine contains lactose anhydrous. It should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
4) Patients on dialysis
2. Administer with caution to the following patients:
1) Administration in patients with decreased body volume and renal dysfunction
This drug may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients receiving SGLT-2 inhibitors, including this drug, and some required hospitalization and dialysis. The risk of hypovolemia or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2), the elderly, and those using loop diuretics. For patients with these characteristics, it is necessary to evaluate body fluid status and renal function before starting treatment with this drug, and monitor symptoms and signs of hypotension and renal function after starting treatment.
The glucose-lowering efficacy of this medicine depends on renal function. Efficacy is reduced in patients with moderate renal impairment, and this medicine is not recommended solely for glycemic control in patients with type 2 diabetes and an eGFR below 45 mL/min/1.73 m² (see Dosage and Administration). Among patients with moderate renal impairment, elevated creatinine, phosphorus and parathyroid hormone (PTH) levels and hypotension were reported more frequently with this medicine than with placebo.
There is limited experience in starting this drug in patients with an eGFR of less than 25mL/min/1.73m2.
It is not recommended to start treatment with this drug in patients with chronic heart failure and chronic kidney disease whose eGFR is less than 25mL/min/1.73m2 (see Dosage and Administration section).
3. Adverse reactions
1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with type 2 diabetes (DECLARE; see section ‘11. Information for experts, 3) Clinical trial information’), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the median exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure.
The most commonly reported adverse reactions throughout clinical studies were genital infections.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with chronic heart failure with reduced left ventricular systolic function (LVEF≤40%) (DAPA-HF; see section ‘11. Information for experts, 3) Clinical trial information’), 2,368 people were administered dapagliflozin 10 mg and 2,368 people were administered placebo, and the median exposure period was 18 months. The study population included patients with type 2 diabetes or without diabetes and an eGFR of 30 mL/min/1.73m2 or higher.
In a clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with heart failure whose left ventricular ejection fraction (LVEF) exceeded 40% (DELIVER; see section ‘11. Information for experts, 3) Clinical trial information’), 3,126 people were administered dapagliflozin 10 mg and 3,127 people were administered placebo, and the median exposure period was 27 months. The study population included patients with type 2 diabetes or without diabetes and an eGFR of 25 mL/min/1.73m2 or higher.
In a clinical trial to evaluate the renal effects of dapagliflozin in patients with chronic kidney disease (DAPA-CKD; see section ‘11. Information for experts, 3) Clinical trial information’), 2,149 people were administered dapagliflozin 10 mg and 2,149 people were administered placebo, and the median exposure period was 27 months. The study population included patients with type 2 diabetes or without diabetes and an eGFR greater than 25 mL/min/1.73m2 or less than 75 mL/min/1.73m2. Treatment was continued when eGFR decreased below 25 mL/min/1.73m2.
The safety profile of dapagliflozin was consistent across the efficacy and effects studied. Diabetic ketoacidosis was observed only in diabetic patients.
2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and unknown (cannot be assessed from available data).
Table 1 Adverse Reactions in Placebo-Controlled Trialsa
* Table: refer to manual
3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In the DECLARE clinical trial, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
In the DAPA-HF clinical trial, no serious adverse events of genital infection were reported in the dapagliflozin group and one case was reported in the placebo group. There were 7 patients (0.3%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In the DELIVER clinical trial, one serious adverse event of genital infection was reported in each group (<0.1%). There were 3 patients (0.1%) in the dapagliflozin group and no patients in the placebo group who discontinued treatment due to adverse events of genital infection.
In the DAPA-CKD clinical trial, serious adverse events of genital infection were reported in 3 cases (0.1%) in the dapagliflozin group and none in the placebo group. There were 3 patients (0.1%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In patients without diabetes, no serious adverse events of genital infection or adverse events leading to discontinuation of treatment were reported.
② Low blood sugar
The frequency of hypoglycemia in clinical trials in patients with diabetes depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. In a comprehensive analysis of safety information from 1,169 patients evaluated for dapagliflozin and saxagliptin combination therapy, the overall incidence of hypoglycemia was low at 24 weeks (≤1.8% in all groups).
In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in those receiving dapagliflozin 10 mg and glimepiride (6.0% and 7.9%, respectively) compared to those receiving placebo and glimepiride (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients at weeks 24 and 104, respectively, in patients administered dapagliflozin 10 mg in combination with insulin, and 0.5% were reported at weeks 24 and 104 in patients administered placebo in combination with insulin. Minor hypoglycemic episodes were reported in patients administered dapagliflozin 10 mg in combination with insulin. It was reported in 40.3% and 53.1% at weeks 24 and 104, respectively, and in patients receiving placebo with additional insulin, it was reported in 34.0% and 41.6%.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and in 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
The DECLARE trial showed that dapagliflozin therapy compared with placebo did not increase the risk of major hypoglycemic events. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and in 83 patients (1.0%) in the placebo group.
In the DAPA-HF clinical trial, major hypoglycemic events were reported in 4 patients (0.2%) each in the dapagliflozin and placebo groups, and occurred only in patients with type 2 diabetes. In the DELIVER clinical trial, major hypoglycemic events were reported in 6 patients (0.2%) in the dapagliflozin group and 7 patients (0.2%) in the placebo group. Major hypoglycemic events were observed only in patients with type 2 diabetes.
In the DAPA-CKD clinical trial, major hypoglycemic events were reported in 14 patients (0.7%) in the dapagliflozin group and 28 patients (1.3%) in the placebo group, and were observed only in patients with type 2 diabetes.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In the DECLARE clinical trial, the number of patients who developed adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2, 19 serious adverse events suggesting volume loss were reported in the dapagliflozin group and 13 cases in the placebo group.
In the DAPA-HF clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. The number of patients with serious adverse events suggesting volume loss was lower in the dapagliflozin group (23 patients [1.0%]) than in the placebo group (38 patients [1.6%]). Similar results were observed across subgroups including age, presence of diabetes at baseline, baseline eGFR, and systolic blood pressure. In the DELIVER clinical trial, the number of patients with serious adverse events suggesting a decrease in body fluid volume was 35 (1.1%) in the dapagliflozin group and 31 (1.0%) in the placebo group.
In the DAPA-CKD clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 120 (5.6%) in the dapagliflozin group and 84 (3.9%) in the placebo group. The number of patients with serious adverse events suggesting a decrease in body fluid volume was 16 (0.7%) in the dapagliflozin group and 15 (0.7%) in the placebo group.
④ Diabetic ketoacidosis
In the DECLARE clinical trial (median dapagliflozin exposure period of 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 cases in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients who developed diabetic ketoacidosis in the dapagliflozin group, 22 were taking insulin at the time the case occurred. Factors causing diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see ‘4. General precautions, 3) Ketoacidosis’).
In the DAPA-HF clinical trial, diabetic ketoacidosis cases were reported in 3 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group. In the DELIVER trial, diabetic ketoacidosis cases were reported in 2 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group.
In the DAPA-CKD clinical trial, no cases of diabetic ketoacidosis were reported in the dapagliflozin group and two cases of type 2 diabetes were reported in the placebo group.
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In the DECLARE clinical trial, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg group, which was less frequent than the 109 cases (1.3%) in the placebo group.
In the DAPA-HF clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was small, with no significant difference between the two groups: 14 patients (0.6%) in the dapagliflozin group and 17 patients (0.7%) in the placebo group. There were 5 patients (0.2%) in each of the dapagliflozin and placebo groups who discontinued treatment due to adverse events of urinary tract infection. In the DELIVER clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 41 (1.3%) in the dapagliflozin group and 37 (1.2%) in the placebo group. The number of patients who discontinued treatment due to adverse events of urinary tract infection was 13 (0.4%) in the dapagliflozin group and 9 (0.3%) in the placebo group.
In the DAPA-CKD clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 29 (1.3%) in the dapagliflozin group and 18 (0.8%) in the placebo group. There were 8 patients (0.4%) in the dapagliflozin group and 3 (0.1%) in the placebo group who discontinued treatment due to adverse events of urinary tract infection.
? Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. According to pooled safety data from 13 clinical trials, these adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal insufficiency (eGFR 60 mL/min/1.73m2 or higher), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse reactions were reported more frequently in patients with an eGFR greater than 30 mL/min/1.73m2 but less than 60 mL/min/1.73m2 (18.5% and 9.3% for dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In the DECLARE clinical trial, which included elderly patients and patients with renal impairment (eGFR less than 60 mL/min/1.73m2), eGFR decreased over time in both the dapagliflozin group and the placebo group. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.
In the DAPA-HF clinical trial and the DELIVER clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. In the DAPA-HF clinical trial, the initial decrease in average eGFR was -4.3 mL/min/1.73m2 in the dapagliflozin group and -1.1 mL/min/1.73m2 in the placebo group. At 20 months, the change from baseline in eGFR was similar between treatment groups (dapagliflozin group -5.3 mL/min/1.73m2, placebo group -4.5 mL/min/1.73m2). In the DELIVER clinical trial, the average decrease in eGFR at 1 month was -3.7 mL/min/1.73m2 in the dapagliflozin group and -0.4 mL/min/1.73m2 in the placebo group. The change from baseline in eGFR at 24 months was similar between treatment groups (dapagliflozin group -4.2 mL/min/1.73m2, placebo group -3.2 mL/min/1.73m2).
In the DAPA-CKD clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in average eGFR was -4.0 mL/min/1.73 m2 in the dapagliflozin group and -0.8 mL/min/1.73 m2 in the placebo group. The change from baseline in eGFR at 28 months was -7.4 mL/min/1.73m2 in the dapagliflozin group and -8.6 mL/min/1.73m2 in the placebo group.
⑦ Perineal gangrene (Fournier’s gangrene)
During post-marketing surveillance, cases of Fournier's gangrene have been reported in patients receiving SGLT2 inhibitors, including dapagliflozin (see 4. General precautions, 12) Perineal gangrene (Fournier's gangrene).
In the DECLARE clinical trial involving 17,160 patients with type 2 diabetes and a median exposure period of 48 months, a total of 6 cases of Fournier's gangrene were reported, including 1 case in the dapagliflozin group and 5 cases in the placebo group.
4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis (including diabetic ketoacidosis)
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
- Angioedema
5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,027 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.59% (805/3,027 people, total 1,122 cases) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
4. General precautions
1) Use for patients with hepatic impairment
Clinical trial experience in patients with hepatic impairment is limited. Dapagliflozin exposure is increased in patients with severe hepatic impairment.
2) Use in patients at risk of volume loss and/or hypotension
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients who may be at risk for drug-induced reductions in blood pressure, such as patients receiving antihypertensive treatment and a history of hypotension or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal disease), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte testing) is recommended. For patients exhibiting volume loss, temporary discontinuation of dapagliflozin is recommended until volume loss is restored.
3) Ketoacidosis
Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Ketoacidosis associated with this medicine may occur even when blood glucose is below 250 mg/dL. Patients treated with this medicine who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue this medicine, assess the patient’s condition and initiate treatment promptly.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement.
In many post-marketing reports, particularly in patients with type 1 diabetes, the presence or absence of ketoacidosis was not immediately identified and the introduction of treatment was delayed because the observed blood glucose levels were lower than those typically expected in diabetic ketoacidosis (most often less than 250 mg/dL). Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting treatment with this medication, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with this drug for the development of ketoacidosis, and consider temporarily discontinuing dapagliflozin administration if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.
Inform patients about the risk of diabetic ketoacidosis, its risk factors, signs and symptoms, and the fact that it may occur even when blood glucose is below 250 mg/dL. It is recommended that patients be able to monitor blood ketones and receive education on when monitoring is needed. Patients should seek prompt treatment if ketoacidosis is suspected.
4) Urosepsis and pyelonephritis
Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.
5) Reproductive infections (including fungi)
Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.
6) Elderly patients
Elderly patients are more likely to have renal impairment or be taking antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE-I) and type 1 angiotensin II receptor inhibitors (ARBs). The same recommendations regarding renal function apply to elderly patients as to all patients.
Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics.
From a pharmacokinetic perspective, there are insufficient data to make conclusions regarding blood drug exposure in patients over 70 years of age.
7) Urine laboratory evaluation
Patients receiving this drug will test positive for urinary glucose due to its mechanism of action.
8) Use of drugs known to cause hypoglycemia
Insulin secretagogues such as insulin and sulfonylureas cause hypoglycemia. Therefore, when used in combination with this drug, the dose of insulin or insulin secretagogue may need to be reduced to reduce the risk of hypoglycemia.
9) SGLT2 inhibitors such as this drug may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine output. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.
10) Weight loss
In a 24-week, placebo-controlled study of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes, the change in body weight from baseline was −3.16 kg with dapagliflozin and −2.19 kg with placebo, indicating greater weight loss with dapagliflozin.
11) Lower limb amputation
In long-term clinical studies of other SGLT2 inhibitors in patients with type 2 diabetes, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. It is important to discuss routine preventive foot care with patients with diabetes.
12) Perineal gangrene (Fournier’s gangrene)
In post-marketing surveillance of diabetic patients taking SGLT2 inhibitors, although rare, severe, life-threatening perineal gangrene requiring prompt surgical intervention was reported (see 3. Adverse Reactions, 3) Description of Specific Adverse Reactions, ⑦ Perineal Gangrene (Fournier's Gangrene)). Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving this drug develops pain, maceration, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. Administration of dapagliflozin should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.
5. Drug interactions
1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylurea can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.
2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.
3) Effect of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.
4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor serum lithium levels.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.
5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.
6) Pediatric
Interaction studies were conducted only in adults.
7) Interference with 1,5-anhydroglucitol test
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.
6. Administration to pregnant and lactating women
1) Pregnant women
There are no data on dapagliflozin administered to pregnant women. Studies on rats showed toxicity to kidney development during the second and third trimesters of human pregnancy. The use of dapagliflozin in pregnant women is not recommended. Once pregnancy is confirmed, dapagliflozin administration should be discontinued.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
2) Nursing mothers
It is not known whether dapagliflozin and its metabolites are passed into human milk. Pharmacodynamic/toxicological data in animals indicate excretion of dapagliflozin/metabolite in milk and pharmacologically mediated effects in nursing offspring. Risk to neonates/infants cannot be excluded. Dapagliflozin should not be used during breastfeeding.
7. Administration to children
The safety and efficacy of dapagliflozin in pediatric patients have not been established.
8. Treatment in case of overdose
Dapagliflozin did not show any toxicity at single oral doses of up to 500 mg (50 times the maximum recommended human dose) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In a clinical trial in which healthy subjects and patients with type 2 diabetes were administered up to 100 mg (10 times the maximum recommended human dose) once daily for 2 weeks, the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.
9. Application precautions
Dapagliflozin has no or little effect on the ability to drive or use machines. Patients should be aware of the risk of hypoglycemia when administering dapagliflozin in combination with sulfonylurea or insulin.
10. Precautions for storage and handling
1) Store out of reach of children.
2) It is not advisable to change the container as it may damage the quality of the product or cause an accident. Store in original container.
11. Information for experts
1) Mechanism of action: Dapagliflozin is a very potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose-cotransporter 2 (SGLT2). Inhibition of SGLT2 by dapagliflozin reduces the reabsorption of glucose from the glomerular filtrate in the proximal renal tubules and simultaneously reduces sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis. Therefore, dapagliflozin increases the delivery of sodium to the distal tubule, which increases the tubuloglomerular feedback and reduces intraglomerular pressure. This, together with osmotic diuresis, results in reduced volume overload, decreased blood pressure, and lower preload and afterload, which may have beneficial effects on cardiac remodeling and diastolic function and preserve renal function. Other effects include increased hematocrit and weight loss.
The heart and kidney benefits of dapagliflozin do not depend solely on its hypoglycemic effects and are not limited to patients with diabetes.
Dapagliflozin reduces glucose reabsorption in the kidneys, resulting in urinary glucose excretion, thereby improving fasting and postprandial plasma glucose levels. This glucose excretion is observed upon the first administration of the drug and is maintained throughout the 24-hour dosing interval and continues throughout the treatment period. The amount of glucose eliminated by the kidneys through this mechanism is dependent on blood glucose concentration and GFR. Accordingly, the amount of glucose that is filtered is small and is reabsorbed by the SGLT1 transporter and unblocked SGLT2, so dapagliflozin appears to have a low tendency to cause hypoglycemia in subjects with normal blood sugar and/or low eGFR. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycemia. The action of dapagliflozin is unrelated to insulin secretion and action. Improvements in homeostatic model assessments of beta cell (HOMA beta cell) function were observed in clinical trials of dapagliflozin.
SGLT2 is selectively expressed in the kidney. Dapagliflozin does not inhibit other glucose transporters important for glucose transport to peripheral tissues and is more than 1,400-fold selective for SGLT2 compared to SGLT1, the main transporter responsible for glucose absorption in the digestive tract.
2) Pharmacokinetic information:
① Absorption: Dapagliflozin is rapidly absorbed after oral administration. The highest concentration of dapagliflozin in the blood (Cmax) was generally achieved within 2 hours when administered on an empty stomach. Cmax and AUC increase proportionally with dapagliflozin dose. When administered orally at 10 mg, the bioavailability of dapagliflozin was 78%, and when administered with a high-fat diet, the Cmax of dapagliflozin was reduced by up to 50% compared to fasting, Tmax was delayed by about 1 hour, and AUC was unchanged. This difference is not considered to have clinical significance.
② Distribution: The protein binding rate of dapagliflozin is approximately 91% and does not vary depending on the disease state (e.g. renal or hepatic impairment, etc.).
③ Metabolism: Dapagliflozin is extensively metabolized and mainly produces dapagliflozin 3-O-glucuronide, an inactive metabolite. Dapagliflozin 3-O-glucuronide or other metabolites do not contribute to the hypoglycemic effect. The mediator that forms dapagliflozin 3-O-glucuronide is UGT1A9, an enzyme found in the liver and kidneys, and CYP-mediated metabolism accounts for a small percentage of the metabolic pathways in the human body.
④ Excretion: The terminal elimination half-life (t1/2) of dapagliflozin was 12.9 hours, and the systemic clearance rate after administration of dapagliflozin was 207ml/min. Dapagliflozin and related metabolites are mainly excreted through urine, of which less than 2% is unmetabolized. When 50 mg of 14C-dapagliflozin was administered, a total of 96% was recovered, including 75% from urine and 21% from feces. In feces, approximately 15% of the dose was in unmetabolized form.
⑤ Renal impairment: In steady state (20 mg once daily, dapagliflozin administered for 7 days), the average body exposure to dapagliflozin was 32%, 60%, and 87% higher in test subjects with type 2 diabetes and mild, moderate, or severe renal dysfunction (measured by plasma clearance of iohexol) compared to type 2 diabetic patients with normal renal function. During 24 hours at steady state, urinary glucose excretion was very dependent on the state of renal function and was 85, 52, 18, and 11 g (glucose/day) in subjects with normal renal function, mild, moderate, and severe renal impairment, respectively. The effect of hemodialysis on dapagliflozin exposure is unknown. The effect of renal function decline on systemic exposure was evaluated using a population pharmacokinetic model. Consistent with previous results, the predicted AUC of this model was higher in patients with chronic kidney disease than in patients with normal renal function, and was not significantly different in patients with chronic kidney disease with or without type 2 diabetes.
⑥ Hepatic impairment: In subjects with mild or moderate hepatic impairment (Child-Pugh Class A, B), the Cmax and AUC of dapagliflozin were 12% and 36% higher, respectively, compared to subjects with normal liver function. This is not judged to be a clinically significant difference. In subjects with severe hepatic impairment (Child-Pugh Class C), the mean Cmax and AUC of dapagliflozin were 40% and 67% higher, respectively, compared to subjects with normal liver function.
3) Clinical trial information
To evaluate the blood sugar-lowering effectiveness and safety of dapagliflozin, 13 double-blind, randomized, controlled clinical trials were conducted on 6,362 type 2 diabetes patients, of which 4,273 received dapagliflozin. Twelve studies had a treatment period of 24 weeks, and eight of these were extended to long-term trials with an additional treatment period of 24 to 80 weeks (up to 104 weeks). One trial was a 52-week trial and was extended to 52 and 104 weeks. Additionally, two 24-week double-blind, randomized, controlled clinical trials were conducted to evaluate the efficacy and safety of the combined administration of saxagliptin and dapagliflozin in 854 patients with type 2 diabetes.
To evaluate the effect of dapagliflozin 10 mg compared to placebo on cardiovascular and kidney-related events, a clinical trial (DECLARE) was conducted in 17,160 patients with type 2 diabetes with confirmed cardiovascular disease or cardiovascular risk factors.
Monotherapy
A 24-week, double-blind, randomized, placebo-controlled study, followed by an extension, evaluated the efficacy and safety of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes. Once-daily dapagliflozin produced a statistically significant reduction in glycated hemoglobin (HbA1c) compared with placebo (p < 0.0001; see Table 2).
In an additional extension study, the HbA1c reduction was maintained at week 102 (adjusted mean reduction from baseline: -0.61% and -0.17% for dapagliflozin 10 mg and placebo, respectively).
Table 2 Outcomes at 24 weeks (LOCFa) in a placebo-controlled study of dapagliflozin monotherapy in patients with inadequate glycemic control
* Table: refer to manual
Combination therapy with other hypoglycemic agents
Initial combination therapy with metformin
Two 24-week active-controlled studies were conducted to evaluate the efficacy and safety of initial combined administration of dapagliflozin and extended-release metformin in patients with type 2 diabetes who had no prior drug treatment. When dapagliflozin 10 mg and metformin were administered together, HbA1c was significantly reduced compared to each administration alone (see Table 3).
Table 3 Outcomes at 24 weeks in an active-controlled study of initial combination therapy with dapagliflozin and extended-release metformin in drug-naïve patients (LOCFa)
* Table: refer to manual
An active-controlled trial comparing dapagliflozin plus the addition of a sulfonylurea (glipizide) in patients with inadequate glycemic control on metformin.
A 52-week active control non-inferiority study (52 weeks and 104 weeks extension) was conducted to compare and evaluate the additional use of dapagliflozin and sulfonylurea (glipizide) to metformin in patients with type 2 diabetes who had insufficient glycemic control with metformin (HbA1c greater than 6.5% but less than 10%). As a result, dapagliflozin demonstrated non-inferiority by showing a similar reduction in HbA1c compared to baseline at 52 weeks as glipizide (see Table 4). At week 104, the reduction in HbA1c compared to baseline was -0.32% for dapagliflozin and -0.14% for glipizide. The incidence of one or more hypoglycemic events was significantly lower in the dapagliflozin group (3.5% and 4.3% for 52 and 104 weeks, respectively) than in the glipizide group (40.8% and 47.0% for 52 and 104 weeks, respectively).
Table 4 Outcomes at Week 52 (LOCFa) in an active-controlled study comparing dapagliflozin plus each additional sulfonylurea (glipizide) in patients with inadequate glycemic control on metformin
* Table: refer to manual
Additional combination therapy with other hypoglycemic agents
Dapagliflozin includes metformin (see Table 5), sulfonylurea (glimepiride; see Table 6), insulin (alone or in combination with oral hypoglycemic agents; see Table 7), sitagliptin (alone or in combination with metformin; see Table 8), metformin and sulfonylurea (see Table 9), metformin and saxagliptin (see Table 10), and pioglitazone. When administered in combination with (see Table 11), there was a statistically significant decrease in HbA1c compared to placebo at 24 weeks (p <0.0001).
In a trial in which dapagliflozin was added to metformin, the HbA1c reduction effect was maintained even at 102 weeks. The HbA1c reduction effect was maintained even when the test using the drug in combination with glimepiride was extended to 48 weeks, and the study using the drug in combination with insulin was extended to 104 weeks.
Table 5 Outcomes at 24 weeks (LOCFa) in a placebo-controlled study comparing the addition of dapagliflozin in patients with inadequate glycemic control on metformin monotherapy
* Table: refer to manual
Table 6 Outcomes at 24 weeks (LOCFa) in a placebo-controlled study comparing the addition of dapagliflozin in patients with inadequate glycemic control on sulfonylurea (glimepiride) monotherapy (LOCFa)
* Table: refer to manual
Table 7 Placebo-controlled study comparing add-on dapagliflozin in patients with inadequate glycemic control with insulin (alone or in combination with oral hypoglycemic agents), outcomes at 24 weeks (LOCFa)
* Table: refer to manual
Table 8 Outcomes at Week 24 (LOCFa) in a placebo-controlled study comparing the add-on of dapagliflozin in patients with inadequate glycemic control with sitagliptin (alone or in combination with metformin)
* Table: refer to manual
Table 9 Results at Week 24 in a Placebo-Controlled Study Comparing the Add-On of Dapagliflozin in Patients with Inadequate Glycemic Control on Metformin and Sulfonylureas
* Table: refer to manual
Table 10 Results at Week 24 in a Placebo-Controlled Study Comparing the Add-On of Dapagliflozin in Patients with Inadequate Glycemic Control with Saxagliptin and Metformin
* Table: refer to manual
Table 11 Outcomes at Week 24 (LOCFa) in a Placebo-Controlled Study Comparing the Add-On of Dapagliflozin in Patients with Inadequate Glycemic Control with Pioglitazone
* Table: refer to manual
Patients with moderate renal impairment stage 3A (eGFR 45-60mL/min/1.73m2)
In a study limited to diabetic patients with an eGFR of 45 to 60 mL/min/1.73 m2, the effectiveness of additional administration of dapagliflozin was evaluated in patients whose glycemic control was inadequate with existing therapy. Dapagliflozin showed a decrease in HbA1c as shown in Table 12 compared to placebo.
Table 12 Results at 24 weeks in a placebo-controlled study confirming the effect of dapagliflozin in diabetic patients with eGFR 45-60mL/min/1.73m2
* Table: refer to manual
fasting blood sugar
When dapagliflozin 10 mg was administered alone or in combination with metformin, glimepiride, metformin and sulfonylurea, sitagliptin (alone or in combination with metformin), saxagliptin and metformin or insulin, it statistically significantly reduced fasting blood sugar compared to placebo. This effect was maintained throughout the trial, which extended from the first week of administration to 104 weeks.
In a study limited to diabetic patients with an eGFR of 45 to 60 mL/min/1.73 m2, the fasting blood sugar value at 24 weeks of administration was -0.27 mmol/L (-4.87 mg/dL) for placebo and -1.19 mmol/L (-21.46 mg/dL) for dapagliflozin.
postprandial blood sugar
When dapagliflozin 10 mg was administered in combination with glimepiride or sitagliptin (alone or in combination with metformin), a decrease in 2-hour postprandial blood glucose was observed at 24 weeks and maintained until 48 weeks.
Effects on the cardiovascular system and kidneys
The DECLARE study was a multinational, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted to determine the effects of dapagliflozin compared to placebo on the cardiovascular system and kidneys when added to existing treatment regimens. In addition to type 2 diabetes, all patients had at least two cardiovascular risk factors (men over 55 years of age or women over 60 years of age, at least one of dyslipidemia, hypertension, or current smoking) or had cardiovascular disease.
Among the 17,160 patients, 6,974 (40.6%) had cardiovascular disease and 10,186 (59.4%) did not have cardiovascular disease. 8,582 people were randomly assigned to receive dapagliflozin 10 mg and 8,578 were randomly assigned to placebo. The median follow-up period was 4.2 years.
The average age of the group participating in the study was 63.9 years, of which 37.4% were women. The average duration of diabetes for all patients was 11.9 years, and 22.4% had diabetes for less than 5 years. The average HbA1c was 8.3% and the average body mass index was 32.1 kg/m2.
At baseline, 10.0% of patients had a history of heart failure. The average eGFR was 85.2 mL/min/1.73m2. 7.4% of patients had an eGFR less than 60 mL/min/1.73m2, and 30.3% of patients had microalbuminuria [urinary albumin-to-creatinine ratio (UACR) of 30 mg/g or more - 300 mg/g or less] or macroalbuminuria (UACR of 300 mg/g). There was an excess).
Most patients (98%) were receiving at least one medicine for diabetes at baseline: 82% were taking metformin, 41% insulin and 43% a sulfonylurea.
Approximately 81.3% of patients received an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 75.0% a statin, 61.1% an antiplatelet agent, 55.5% aspirin, 52.6% a beta-blocker, 34.9% a calcium channel blocker, 22.0% a thiazide diuretic and 10.5% a loop diuretic.
Major cardiovascular events
Dapagliflozin 10 mg demonstrated non-inferiority to placebo for the composite endpoint of adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke (one-sided p<0.001).
Hospitalization due to heart failure or death from cardiovascular disease
Dapagliflozin 10 mg was superior to placebo for the primary composite endpoint of preventing hospitalization for heart failure or cardiovascular death (Figure 1).
In an exploratory analysis of each factor, a significant decrease in the incidence of hospitalization due to heart failure contributed to the difference in treatment effect, and there was no significant difference in cardiovascular disease mortality.
The treatment benefit of dapagliflozin compared to placebo was observed regardless of baseline cardiovascular disease and underlying heart failure, and was consistent across key subgroups including age, gender, renal function (eGFR), and region.
Figure 1. Time to first hospitalization for heart failure or death from cardiovascular disease.
* Figure 1: Refer to manual
Number of patients: patients at risk at the beginning of each interval
nephropathy
Height-related endpoints were evaluated for exploratory purposes.
Dapagliflozin reduced the incidence of multiple events, including confirmed persistent eGFR decline, end-stage renal disease, and renal or cardiovascular death. Differences between treatment groups were seen in the reduction of renal events, including persistent eGFR decline, end-stage renal disease, and kidney-related death.
The hazard ratio (HR) for dapagliflozin compared with placebo for time to nephropathy event (persistent eGFR decline, end-stage renal disease, or kidney-related death) was 0.53 [95% CI 0.43, 0.66].
In patients without a history of albuminuria, dapagliflozin reduced the new onset of persistent albuminuria (UACR > 30 mg/g) compared to placebo (hazard ratio (HR) 0.79 [95% CI 0.72, 0.87]), and in patients with a history of macroalbuminuria, the reduction in macroalbuminuria was greater in the dapagliflozin group than in the placebo group (hazard ratio (HR) 1.82 [95% CI 1.51, 2.20]).
chronic heart failure
DAPA-HF clinical trial: left ventricular ejection fraction ≤40% (LVEF≤40%) heart failure
DAPA-HF was a multinational, multicenter, randomized, double-blind, placebo-controlled study that evaluated the effect of dapagliflozin compared to placebo on the incidence of cardiovascular death and worsening of heart failure when added to standard treatment in patients with heart failure (NYHA functional class II to IV) with reduced left ventricular systolic function (left ventricular ejection fraction [LVEF] 40% or less).
Among 4,744 patients, 2,373 were randomly assigned to dapagliflozin 10 mg and 2,371 to placebo and were treated for a median of 18 months. The average age of the test group was 66 years, and 77% were male.
At baseline, 67.5% of patients were NYHA class II, 31.6% were class III, and 0.9% were class IV, median LVEF was 32%, 56% of heart failure was ischemic, 36% was non-ischemic, and 8% had unknown etiology. 42% of patients in each treatment group had a history of type 2 diabetes, and an additional 3% of patients in each group were classified as having type 2 diabetes based on the criteria of HbA1c ≥ 6.5% applied at the time of subject registration and randomization. 94% of patients were being treated with ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors (ARNI; 11%), 96% with beta-blockers, 71% with mineralocorticoid receptor antagonists, 93% with diuretics, and 26% had an implanted device with defibrillator function.
Patients with an eGFR of 30 mL/min/1.73 m2 or higher at the time of recruitment were included in the study. The average eGFR was 66 mL/min/1.73 m2, 41% of patients had eGFR less than 60 mL/min/1.73 m2, and 15% had eGFR less than 45 mL/min/1.73 m2.
Death from cardiovascular disease and worsening heart failure
Dapagliflozin reduced the incidence of the primary composite endpoint of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure (HR 0.74 [95% CI 0.65, 0.85], p < 0.0001).
The event curves for dapagliflozin and placebo initially spaced out and continued throughout the trial (Figure 2).
Figure 2 Time to first composite event of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure.
* Figure 2: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
Number of patients: patients at risk at the beginning of each interval
Each of the three components comprising the primary composite endpoint all indicated treatment effectiveness. Emergency hospital visits due to heart failure were reduced (Figure 3).
Figure 3 Treatment effect on primary endpoints and components and all-cause mortality.
* Figure 3: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up.
The p-values for each component and for all-cause mortality are nominal.
Dapagliflozin also reduced the total number of hospitalizations for heart failure (first-episode and recurrent) and cardiovascular disease deaths; There were 567 cases in the dapagliflozin group and 742 cases in the placebo group (rate ratio (RR) 0.75 [95% CI 0.65, 0.88]; p = 0.0002).
The therapeutic benefit of dapagliflozin was shown in both heart failure patients with type 2 diabetes and heart failure patients without diabetes.
Dapagliflozin reduced the incidence of the primary composite endpoint by HR 0.75 [95% CI 0.63, 0.90] in patients with diabetes and by HR 0.73 [95% CI 0.60, 0.88] in patients without diabetes.
Additionally, the treatment benefit of dapagliflozin compared to placebo for the primary endpoint was consistent across key subgroups, including heart failure combination therapy, renal function (eGFR), age, gender, and region.
DELIVER clinical trial: Heart failure with left ventricular ejection fraction >40% (LVEF>40%)
DELIVER was a multinational, multicenter, randomized, double-blind, placebo-controlled study that evaluated the effect of dapagliflozin compared to placebo on the incidence of cardiovascular death and worsening heart failure when added to standard treatment in patients aged 40 years or older with heart failure (NYHA functional class II to IV) with LVEF greater than 40%.
Among 6,263 patients, 3,131 were randomly assigned to dapagliflozin 10 mg and 3,132 to placebo and were treated for a median of 28 months. The trial includes 654 (10%) patients with subacute heart failure (defined as patients randomized during hospitalization for heart failure or within 30 days of discharge).
The average age of the test population was 72 years, 56% were male, 71% were white, 3% were black or African American, and 20% were Asian.
At baseline, 75% of patients were NYHA class II, 24% were class III, and 0.3% were class IV, and the median LVEF was 54%. 34% of patients had LVEF 49% or less, 36% of patients had LVEF 50-59%, and 30% had LVEF 60% or more. In each treatment group, 45% had a history of type 2 diabetes. Concomitant medications included ACE inhibitors/ARBs/ARNIs (77%), beta-blockers (83%), diuretics (98%), and mineralocorticoid receptor antagonists (43%).
Patients with an eGFR of 25 mL/min/1.73 m2 or higher at the time of recruitment were included in the study. The average eGFR was 61 mL/min/1.73 m2, 49% of patients had an eGFR less than 60 mL/min/1.73 m2, 23% had an eGFR less than 45 mL/min/1.73 m2, and 3% had an eGFR less than 30 mL/min/1.73 m2.
Death from cardiovascular disease and worsening heart failure
Dapagliflozin was superior to placebo in the primary composite endpoint, reduction in the incidence of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure (HR 0.82 [95% CI 0.73, 0.92], p=0.0008). The event curves were initially separated for dapagliflozin and placebo and this separation was maintained throughout the trial (Figure 4).
Figure 4 Time to first composite event of cardiovascular death, hospitalization for heart failure, or emergency hospital visit for heart failure.
* Figure 4: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
Number of patients: patients at risk at the beginning of each interval
The treatment effect on the primary composite endpoint and its components is shown in Figure 5.
Figure 5 Treatment effects on primary composite endpoints and components
* Figure 5: Refer to manual
Emergency hospital visit for heart failure: Defined as urgent, unscheduled, at the discretion of the attending physician (e.g., emergency room), and whether treatment was needed to prevent worsening heart failure other than simply increasing the dose of oral diuretics.
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up.
The p-value for each component is nominal. Cardiovascular disease mortality, a component of the primary endpoint, was tested as a secondary endpoint under formal Type I error control.
Dapagliflozin was superior to placebo in reducing the total number of heart failure exacerbation events (first hospitalization and readmission for heart failure or emergency hospital visit for heart failure) and cardiovascular deaths; There were 815 cases in the dapagliflozin group and 1,057 cases in the placebo group (incidence rate ratio 0.77 [95% CI 0.67, 0.89]; p=0.0003).
The treatment benefit of dapagliflozin compared to placebo for the primary endpoint was observed in all subgroups: patients with LVEF ≤49%, patients with LVEF 50-59%, and patients with LVEF ≥60%. The effect was consistent in other major subgroups (age, gender, NYHA class, NT-proBNP level, subacute status, type 2 diabetes, renal function (eGFR), etc.).
chronic kidney disease
DAPA-CKD is a multinational, multicenter, event-based study comparing dapagliflozin to placebo when added to background standard therapy in patients with chronic kidney disease (CKD) with eGFR ≥25 mL/min/1.73 m2 but ≤75 mL/min/1.73 m2 and albuminuria (urinary albumin creatinine ratio [UACR] ≥200 mg/g but ≤5,000 mg/g). This was a randomized, double-blind, parallel group, placebo-controlled trial. The primary objective was to measure the effectiveness of dapagliflozin compared to placebo in reducing the composite endpoint of reduction in sustained eGFR greater than 50%, end-stage kidney disease (ESKD) (defined as sustained eGFR less than 15 mL/min/1.73 m2, chronic dialysis treatment, or receiving a kidney transplant), CV death, or kidney-related death.
The trial excluded patients with autosomal dominant or recessive polycystic kidney disease, lupus nephritis, or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and patients who had received cytotoxic treatment, immunosuppression, or immunomodulatory therapy within the previous 6 months.
A total of 4,304 patients were randomized to dapagliflozin 10 mg once daily (N = 2,152) or placebo (N = 2,152) and followed for a median of 28.5 months. Treatment continued during the study even if eGFR fell to 25 mL/min/1.73 m² or below.
At baseline, the mean eGFR was 43.1 mL/min/1.73 m2 and the median UACR was 949.3 mg/g; 44.1% of patients had an eGFR between 30 mL/min/1.73 m2 and less than 45 mL/min/1.73 m2, and 14.5% had an eGFR less than 30 mL/min/1.73 m2. 67.5% of these patients had type 2 diabetes.
Patients were receiving standard therapy: 97.0% were treated with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB). Approximately 44% were taking an antiplatelet agent and 65% a statin.
The average age of the test population was 61.8 years, 66.9% were male, 53.2% were white, 4.4% were black or African American, and 34.1% were Asian.
Dapagliflozin was superior to placebo in reducing the primary composite endpoint of sustained decline in eGFR greater than 50%, leading to ESKD, CV death, or kidney-related death (HR 0.61 [95% CI 0.51, 0.72], p<0.0001). The number of patients requiring treatment per 27 months was 19 (95% CI 15, 27). Based on Kaplan-Meier plots, the event curves for dapagliflozin and placebo began to diverge early (month 4) and continued to diverge throughout the study period (Figure 6).
Figure 6 Primary composite endpoint: Time to first occurrence of sustained decline in eGFR greater than 50%, ESKD, CV death, or kidney-related death.
* Figure 6: Refer to manual
Number of patients: patients at risk at the beginning of each interval
All four components of the primary composite endpoint individually contributed to this treatment effect (Figure 7). Dapagliflozin was associated with the composite endpoint of decreased eGFR >50% sustained, ESKD or kidney-related death (HR 0.56 [95% CI 0.45, 0.68], p<0.0001), composite endpoint of CV death and hospitalization for heart failure (HR 0.71 [95% CI 0.55, 0.92], p=0.0089), and all-cause mortality. It also reduced the incidence of death (HR 0.69 [95% CI 0.53, 0.88], p=0.0035).
Figure 7 Treatment effect related to primary and secondary composite endpoints, their individual components, and all-cause mortality
* Figure 7: Refer to manual
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up.
Risk ratio estimates are not presented for subgroups with a total of less than 15 cases for both groups combined.
The p-value for the components of a composite endpoint is a nominal value.
The therapeutic effect of dapagliflozin was consistent in patients with chronic kidney disease with type 2 diabetes and in patients with chronic kidney disease without diabetes (Figure 8).
Figure 8 Treatment effect in patients with type 2 diabetes and in patients without diabetes
* Figure 8: Refer to manual
The number of initial events for each component represents the number of events for each component that actually occurred, and the number of events for the composite evaluation variable is not added. Risk ratio estimates are not presented for subgroups with a total of less than 15 cases for both groups combined.
Event rate refers to the number of patients who experience an event per 100 person-years of follow-up. The p-value is a nominal value.
The treatment benefit of dapagliflozin compared to placebo with respect to the primary composite endpoint was consistent across key subgroups (Figure 9).
Figure 9 Treatment effect related to primary composite endpoint by subgroup
* Figure 9: Refer to manual
n/N# Number of subjects with events/Number of subjects in subgroup
The treatment benefit of dapagliflozin was also observed for exploratory endpoints:
? A greater reduction in UACR was demonstrated with dapagliflozin compared to placebo. These effects were observed as early as day 14 and were maintained throughout the trial. The adjusted mean percent change from baseline in UACR (mg/g) at month 36 was -41% in patients treated with dapagliflozin and -20% in patients treated with placebo, with a difference between treatment groups of -26.3% ([95% CI -36.8, -14.0], nominal p=0.0001).
? The incidence of serum creatinine doubling (a measure of acute worsening of renal function) from the most recent laboratory measurement was reduced in dapagliflozin compared with placebo (HR 0.68 [95% CI 0.49, 0.94], nominal p=0.0187).
4) Non-clinical safety data
① Carcinogenicity: Dapagliflozin did not induce tumors in mice or rats at any of the doses evaluated in the 2-year carcinogenicity study. The oral doses in mice were 5, 15, and 40 mg/kg/day for males and 2, 10, and 20 mg/kg/day for females, and the oral doses for rats were 0.5, 2, and 10 mg/kg/day for both sexes. The highest dose evaluated in mice corresponded to an AUC exposure multiple of approximately 72 (males) and 105 (female) the human AUC at the maximum recommended human dose (MRHD) of 10 mg per day. The AUC exposure in rats was approximately 131 times (males) and 186 times (females) the human AUC at MRHD.
② Mutagenicity: Dapagliflozin was negative in the Ames mutagenicity test and positive in the in vitro chromosomal abnormality test, but this was true when the concentration was over 100 mg/mL under S9 activity conditions. In particular, dapagliflozin was negative for chromosomal abnormalities in in vivo conditions in micronucleus or DNA repair tests conducted on rats at an exposure equivalent to more than 2,100 times the human exposure in MRHD. These studies support that dapagliflozin does not present a genotoxic risk to humans, given the absence of neoplastic findings in rat and mouse carcinogenicity studies.
③ Reproductive dysfunction: In fertility and early embryo development tests on rats, 15, 75, or 300/210 mg/kg/day of dapagliflozin was administered to males (300 mg/kg/day dose was reduced to 210 mg/kg/day after 4 days), and 3, 15, or 75 mg/kg/day doses were administered to females. Dapagliflozin did not affect mating, fertility, or early embryonic development in males or females at any dose administered (fold exposure ≤1708 and 998 times the MRHD in males and females). However, at 300/210 mg/kg/day, seminal vesicle and epididymal weight decreased, sperm motility and sperm count decreased, and the number of morphologically abnormal sperm was low.
④ Teratogenicity: Direct administration to young rats during the weaning period and indirect exposure to the drug during the second half of pregnancy and lactation (the period corresponding to the second and third trimesters of pregnancy in relation to human kidney development) are associated with an increase in the severity and incidence of renal pelvis dilatation and tubular dilatation in offspring. In a toxicity study in young animals, when dapagliflozin was administered to young rats on the 21st day of life at doses of 1, 15, or 75 mg/kg/day for up to 90 days, renal pelvis dilatation and tubular dilatation were reported at all doses; Exposure to offspring at the lowest dose was more than 15 times the MRHD. These observations were associated with a dose-related increase in kidney mass and macroscopic renal hypertrophy at all doses. The renal pelvis and tubular dilatation observed in young animals were not completely reversed during a recovery period of approximately 1 month.
⑤ Early developmental disorders: In a separate study on prenatal and postnatal development, maternal rats were administered drugs (1, 15, or 75 mg/kg/day) from the 6th day of pregnancy to the 21st day after birth, and the offspring were exposed indirectly through uterus and breastfeeding. (A separate study was conducted to evaluate the effects of dapagliflozin on milk and offspring.) Increased severity or events of renal pelvic dilatation were again observed in adult offspring of dams receiving the dose, albeit only at a dose of 75 mg/kg/day (corresponding to maternal and offspring dapagliflozin exposures of 1415 and 137 times [human levels in MRHD], respectively). Additional developmental toxicity was limited to dose-related reductions in pup body weight, which were observed at doses above 15 mg/kg/day (pup exposure greater than 29 times [human levels in MRHD]). Maternal toxicity was evident only at 75 mg/kg/day and was limited to a transient decrease in body weight and food consumption at the beginning of administration. The NOAEL for developmental toxicity, 1 mg/kg/day, is approximately 19 times the [human level in MRHD] and corresponds to maternal systemic exposure.
In additional embryo-fetal development studies in rats and rabbits, dapagliflozin was administered at intervals corresponding to key periods of organogenesis in each species. No maternal or developmental toxicity was observed in rabbits at any dose administered (20, 60, or 180 mg/kg/day); 180 mg/kg/day corresponds to a systemic exposure approximately 1191 times the MRHD. In rats, dapagliflozin was not embryonic lethal or teratogenic up to a dose of 75 mg/kg/day (approximately 1441 times the MRHD). Maternal and developmental toxicity was associated at a dose of 150 mg/kg/day (approximately 2344 times [human level in MRHD]). Maternal toxicity includes mortality, abnormal clinical signs, and reduction in body weight and food consumption. Developmental toxicities include embryo-fetal mortality, increased fetal malformations and skeletal dysmorphic events, and reduced fetal weight. The malformations are macrovascular malformation, costal and central spinal fusion, and sternum and central sternal duplication. The variation was mainly reduced ossification.
⑥ Animal toxicology: Most effects observed in major repeated-dose toxicity tests on rats and dogs were judged to be accompanied by pharmacologically mediated increases in urinary glucose, and included weight loss and/or decreased body weight gain rate, increased feed consumption, and increased urine volume due to osmotic diuretics. Dapagliflozin was well tolerated when administered orally to rats at a dose of 25 mg/kg/day (more than 346 times the human exposure at MRHD) for up to 6 months and to dogs at a dose of 120 mg/kg/day (more than 3200 times the human exposure at MRHD) for up to 12 months. In addition, as a result of a single-dose test of dapagliflozin, in both rat and dog toxicity tests, dapagliflozin 3-O-glucuronide metabolites were formed at an exposure level (AUC) equivalent to or higher than the expected human dapagliflozin 3-O-glucuronide exposure after administration of dapagliflozin in MRHD. The most notable nonclinical toxicological findings in rats, increased cancellous bone and tissue mineralization (related to increased serum calcium), were observed only at high exposure multiples (>2100-fold based on human exposure at MRHD). Despite reaching an exposure multiple of more than 3200 times the human exposure at MRHD, there were no dose limitations or target organ toxicities in the 12-month dog study.
5) Pharmaceutical equivalence test information
A. A randomized, open-label, two-treatment, two-sequence, two-period crossover study compared the test product, Dapazin 10 mg tablets (dapagliflozin bis-L-proline; KyungDong Pharm Co., Ltd.), with the reference product, Forxiga 10 mg tablets (dapagliflozin propanediol monohydrate; AstraZeneca Korea). Thirty-five healthy adults received a single oral dose under fasting conditions, and plasma dapagliflozin concentrations were measured. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating equivalence.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 2items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 2 | Dapazin Tab. 5mg | Precautions for use | 2025.08.29 | PDF0042_202402722_Precautions for use (Dapa sedative 5mg).pdf |
| 1 | Dapazin Tab. 5mg | Precautions for use | 2025.05.12 | PDFPrecautions for use (Dapa sedative 5mg, 10mg).pdf |